With the recent establishment of a regional headquarters in
In the paper titled “Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells,” IsoPlexis’ first APAC region publication, researchers investigated whether CD19 CAR-T cells that secrete IL-17 show a persistent and enhanced anti-tumor response. The researchers observed that in mice treated with CAR-T cells, cytokine expression measured with IsoPlexis’ CodePlex platform suggested that IL-7 secretion promoted a Th1 functional phenotype to drive anti-tumor activity more effectively.
This initial data generated using IsoPlexis’ CodePlex solution indicates that the platform can provide key insights into cytokine signatures of CAR-T products to characterize function for improved persistence and potency. CodePlex offers vast improvements over other bulk platforms through effortless automation on the IsoSpark system, making sensitive bulk proteomic data accessible to any lab. More updates on the CodePlex platform are expected for next year.
“This initial APAC publication further strengthens IsoPlexis’ expansion in the region and demonstrates key initial interest in the ability for CodePlex’s effortless automation to fit an important proteomic need internationally,” says
“This first APAC publication validates
About
Cautionary Note Regarding Forward Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Such statements can be identified by the use of words such as “confident”, “indicates”, “validates”, “offers”, “further”, “strengthens”, “demonstrates”, ”show”, “capability”, “enabling”, “confident”, “first”, “more”, “potential”, and “ability”. Important factors that could cause actual results to differ materially include: the rate of adoption of the Company's technology by its customers and potential customers as well as the risk factors set forth in the Risk Factors section of the Company's prospectus filed with the
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Source:
2022 GlobeNewswire, Inc., source